OBJECTIVE: To evaluate the efficacy of recombinant interferon beta (IFNbeta)-1a in the treatment of ALS. BACKGROUND: It has been proposed that IFNs affect the progression of ALS by interfering with putative immune mechanisms involved in the pathogenesis of the disease. METHODS:Patients (n = 61) 40 to 70 years of age with a 6- to 24-month history of confirmed ALS with mild to moderate disability received IFNbeta-1a, 12 mIU (n = 31), or placebo (n = 30) subcutaneously three times a week for 6 months and were followed up for an additional 6 months. Patients were assessed after 4, 12, 24, 36, and 48 weeks. Medical Research Council scale, Norris scale, and bulbar scores as well as forced vital capacity were used to assess disability. Selected electrophysiologic measures (latency, amplitude, and duration of the compound muscle action potential) were also used. RESULTS:Twenty patients randomized to IFNbeta-1a and 17 patients givenplacebo completed the study. A total of 16 patients receiving IFNbeta-1a became non-self-supporting compared with 16 onplacebo (52% versus 53%). There were no significant differences between the two treatment groups for any of the measures of disease progression and disability. Deaths were reported in six patients treated with IFNbeta-1a and four patients on placebo. Adverse events were reported more frequently with IFNbeta-1a (77% of patients) compared with placebo (57%), with flu-like symptoms and local erythema being the commonest complaints. CONCLUSIONS: This pilot study suggests that IFNbeta-1a is not effective in the treatment of ALS.
RCT Entities:
OBJECTIVE: To evaluate the efficacy of recombinant interferon beta (IFNbeta)-1a in the treatment of ALS. BACKGROUND: It has been proposed that IFNs affect the progression of ALS by interfering with putative immune mechanisms involved in the pathogenesis of the disease. METHODS:Patients (n = 61) 40 to 70 years of age with a 6- to 24-month history of confirmed ALS with mild to moderate disability received IFNbeta-1a, 12 mIU (n = 31), or placebo (n = 30) subcutaneously three times a week for 6 months and were followed up for an additional 6 months. Patients were assessed after 4, 12, 24, 36, and 48 weeks. Medical Research Council scale, Norris scale, and bulbar scores as well as forced vital capacity were used to assess disability. Selected electrophysiologic measures (latency, amplitude, and duration of the compound muscle action potential) were also used. RESULTS: Twenty patients randomized to IFNbeta-1a and 17 patients given placebo completed the study. A total of 16 patients receiving IFNbeta-1a became non-self-supporting compared with 16 on placebo (52% versus 53%). There were no significant differences between the two treatment groups for any of the measures of disease progression and disability. Deaths were reported in six patients treated with IFNbeta-1a and four patients on placebo. Adverse events were reported more frequently with IFNbeta-1a (77% of patients) compared with placebo (57%), with flu-like symptoms and local erythema being the commonest complaints. CONCLUSIONS: This pilot study suggests that IFNbeta-1a is not effective in the treatment of ALS.
Authors: Jerry Lin; Andrew Diamanduros; Soheli A Chowdhury; Stephen Scelsa; Norman Latov; Saud A Sadiq Journal: J Neurol Date: 2009-02-25 Impact factor: 4.849
Authors: M Garcia-Montojo; S Fathi; G Norato; B R Smith; D B Rowe; M C Kiernan; S Vucic; S Mathers; R P A van Eijk; U Santamaria; M-L Rogers; A Malaspina; V Lombardi; P R Mehta; H-J Westeneng; L H van den Berg; A Al-Chalabi; J Gold; A Nath Journal: J Neurol Sci Date: 2021-02-23 Impact factor: 3.181
Authors: Leonard H van den Berg; Stavros Nikolakopoulos; Ruben Pa van Eijk; Marinus Jc Eijkemans; Dimitris Rizopoulos Journal: Clin Epidemiol Date: 2018-03-19 Impact factor: 4.790
Authors: André Maier; Nikolaus Deigendesch; Kathrin Müller; Jochen H Weishaupt; Alexander Krannich; Robert Röhle; Felix Meissner; Kaaweh Molawi; Christoph Münch; Teresa Holm; Robert Meyer; Thomas Meyer; Arturo Zychlinsky Journal: PLoS One Date: 2015-10-07 Impact factor: 3.240